0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global HER2 Inhibitors Market Research Report 2024
Published Date: May 2024
|
Report Code: QYRE-Auto-8X17482
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global HER2 Inhibitors Market Research Report 2024
BUY CHAPTERS

Global HER2 Inhibitors Market Research Report 2024

Code: QYRE-Auto-8X17482
Report
May 2024
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

HER2 Inhibitors Market

The global HER2 Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for HER2 Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for HER2 Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of HER2 Inhibitors include Biocon, Roche, AbbVie, Merck Sharp & Dohme, Novartis, Mylan, Puma Biotechnology, Pfizer, Boehringer Ingelheim, Johnson & Johnson, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for HER2 Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HER2 Inhibitors.
The HER2 Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global HER2 Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HER2 Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of HER2 Inhibitors Market Report

Report Metric Details
Report Name HER2 Inhibitors Market
Segment by Type
  • Monotherapy
  • Combination Therapy
Segment by Application
  • Stomach Cancer
  • Adenocarcinoma
  • Cellular Cancer
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Biocon, Roche, AbbVie, Merck Sharp & Dohme, Novartis, Mylan, Puma Biotechnology, Pfizer, Boehringer Ingelheim, Johnson & Johnson, Genentech, GlaxoSmithKline
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of HER2 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of HER2 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the HER2 Inhibitors Market report?

Ans: The main players in the HER2 Inhibitors Market are Biocon, Roche, AbbVie, Merck Sharp & Dohme, Novartis, Mylan, Puma Biotechnology, Pfizer, Boehringer Ingelheim, Johnson & Johnson, Genentech, GlaxoSmithKline

What are the Application segmentation covered in the HER2 Inhibitors Market report?

Ans: The Applications covered in the HER2 Inhibitors Market report are Stomach Cancer, Adenocarcinoma, Cellular Cancer, Other

What are the Type segmentation covered in the HER2 Inhibitors Market report?

Ans: The Types covered in the HER2 Inhibitors Market report are Monotherapy, Combination Therapy

1 HER2 Inhibitors Market Overview
1.1 Product Definition
1.2 HER2 Inhibitors by Type
1.2.1 Global HER2 Inhibitors Market Value Comparison by Type (2024-2030)
1.2.2 Monotherapy
1.2.3 Combination Therapy
1.3 HER2 Inhibitors by Application
1.3.1 Global HER2 Inhibitors Market Value by Application (2024-2030)
1.3.2 Stomach Cancer
1.3.3 Adenocarcinoma
1.3.4 Cellular Cancer
1.3.5 Other
1.4 Global HER2 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global HER2 Inhibitors Revenue 2019-2030
1.4.2 Global HER2 Inhibitors Sales 2019-2030
1.4.3 Global HER2 Inhibitors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 HER2 Inhibitors Market Competition by Manufacturers
2.1 Global HER2 Inhibitors Sales Market Share by Manufacturers (2019-2024)
2.2 Global HER2 Inhibitors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global HER2 Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of HER2 Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of HER2 Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of HER2 Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of HER2 Inhibitors, Date of Enter into This Industry
2.8 Global HER2 Inhibitors Market Competitive Situation and Trends
2.8.1 Global HER2 Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest HER2 Inhibitors Players Market Share by Revenue
2.8.3 Global HER2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global HER2 Inhibitors Market Scenario by Region
3.1 Global HER2 Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global HER2 Inhibitors Sales by Region: 2019-2030
3.2.1 Global HER2 Inhibitors Sales by Region: 2019-2024
3.2.2 Global HER2 Inhibitors Sales by Region: 2025-2030
3.3 Global HER2 Inhibitors Revenue by Region: 2019-2030
3.3.1 Global HER2 Inhibitors Revenue by Region: 2019-2024
3.3.2 Global HER2 Inhibitors Revenue by Region: 2025-2030
3.4 North America HER2 Inhibitors Market Facts & Figures by Country
3.4.1 North America HER2 Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America HER2 Inhibitors Sales by Country (2019-2030)
3.4.3 North America HER2 Inhibitors Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe HER2 Inhibitors Market Facts & Figures by Country
3.5.1 Europe HER2 Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe HER2 Inhibitors Sales by Country (2019-2030)
3.5.3 Europe HER2 Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific HER2 Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific HER2 Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific HER2 Inhibitors Sales by Region (2019-2030)
3.6.3 Asia Pacific HER2 Inhibitors Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America HER2 Inhibitors Market Facts & Figures by Country
3.7.1 Latin America HER2 Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America HER2 Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America HER2 Inhibitors Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa HER2 Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa HER2 Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa HER2 Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa HER2 Inhibitors Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global HER2 Inhibitors Sales by Type (2019-2030)
4.1.1 Global HER2 Inhibitors Sales by Type (2019-2024)
4.1.2 Global HER2 Inhibitors Sales by Type (2025-2030)
4.1.3 Global HER2 Inhibitors Sales Market Share by Type (2019-2030)
4.2 Global HER2 Inhibitors Revenue by Type (2019-2030)
4.2.1 Global HER2 Inhibitors Revenue by Type (2019-2024)
4.2.2 Global HER2 Inhibitors Revenue by Type (2025-2030)
4.2.3 Global HER2 Inhibitors Revenue Market Share by Type (2019-2030)
4.3 Global HER2 Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global HER2 Inhibitors Sales by Application (2019-2030)
5.1.1 Global HER2 Inhibitors Sales by Application (2019-2024)
5.1.2 Global HER2 Inhibitors Sales by Application (2025-2030)
5.1.3 Global HER2 Inhibitors Sales Market Share by Application (2019-2030)
5.2 Global HER2 Inhibitors Revenue by Application (2019-2030)
5.2.1 Global HER2 Inhibitors Revenue by Application (2019-2024)
5.2.2 Global HER2 Inhibitors Revenue by Application (2025-2030)
5.2.3 Global HER2 Inhibitors Revenue Market Share by Application (2019-2030)
5.3 Global HER2 Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Biocon
6.1.1 Biocon Company Information
6.1.2 Biocon Description and Business Overview
6.1.3 Biocon HER2 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Biocon HER2 Inhibitors Product Portfolio
6.1.5 Biocon Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche HER2 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Roche HER2 Inhibitors Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 AbbVie
6.3.1 AbbVie Company Information
6.3.2 AbbVie Description and Business Overview
6.3.3 AbbVie HER2 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AbbVie HER2 Inhibitors Product Portfolio
6.3.5 AbbVie Recent Developments/Updates
6.4 Merck Sharp & Dohme
6.4.1 Merck Sharp & Dohme Company Information
6.4.2 Merck Sharp & Dohme Description and Business Overview
6.4.3 Merck Sharp & Dohme HER2 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Sharp & Dohme HER2 Inhibitors Product Portfolio
6.4.5 Merck Sharp & Dohme Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis HER2 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis HER2 Inhibitors Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Mylan
6.6.1 Mylan Company Information
6.6.2 Mylan Description and Business Overview
6.6.3 Mylan HER2 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Mylan HER2 Inhibitors Product Portfolio
6.6.5 Mylan Recent Developments/Updates
6.7 Puma Biotechnology
6.7.1 Puma Biotechnology Company Information
6.7.2 Puma Biotechnology Description and Business Overview
6.7.3 Puma Biotechnology HER2 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Puma Biotechnology HER2 Inhibitors Product Portfolio
6.7.5 Puma Biotechnology Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Company Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer HER2 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Pfizer HER2 Inhibitors Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Boehringer Ingelheim
6.9.1 Boehringer Ingelheim Company Information
6.9.2 Boehringer Ingelheim Description and Business Overview
6.9.3 Boehringer Ingelheim HER2 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Boehringer Ingelheim HER2 Inhibitors Product Portfolio
6.9.5 Boehringer Ingelheim Recent Developments/Updates
6.10 Johnson & Johnson
6.10.1 Johnson & Johnson Company Information
6.10.2 Johnson & Johnson Description and Business Overview
6.10.3 Johnson & Johnson HER2 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Johnson & Johnson HER2 Inhibitors Product Portfolio
6.10.5 Johnson & Johnson Recent Developments/Updates
6.11 Genentech
6.11.1 Genentech Company Information
6.11.2 Genentech Description and Business Overview
6.11.3 Genentech HER2 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Genentech HER2 Inhibitors Product Portfolio
6.11.5 Genentech Recent Developments/Updates
6.12 GlaxoSmithKline
6.12.1 GlaxoSmithKline Company Information
6.12.2 GlaxoSmithKline Description and Business Overview
6.12.3 GlaxoSmithKline HER2 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.12.4 GlaxoSmithKline HER2 Inhibitors Product Portfolio
6.12.5 GlaxoSmithKline Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 HER2 Inhibitors Industry Chain Analysis
7.2 HER2 Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 HER2 Inhibitors Production Mode & Process
7.4 HER2 Inhibitors Sales and Marketing
7.4.1 HER2 Inhibitors Sales Channels
7.4.2 HER2 Inhibitors Distributors
7.5 HER2 Inhibitors Customers
8 HER2 Inhibitors Market Dynamics
8.1 HER2 Inhibitors Industry Trends
8.2 HER2 Inhibitors Market Drivers
8.3 HER2 Inhibitors Market Challenges
8.4 HER2 Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global HER2 Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global HER2 Inhibitors Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global HER2 Inhibitors Market Competitive Situation by Manufacturers in 2023
 Table 4. Global HER2 Inhibitors Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global HER2 Inhibitors Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global HER2 Inhibitors Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global HER2 Inhibitors Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market HER2 Inhibitors Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of HER2 Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of HER2 Inhibitors, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of HER2 Inhibitors, Product Type & Application
 Table 12. Global Key Manufacturers of HER2 Inhibitors, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global HER2 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HER2 Inhibitors as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global HER2 Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global HER2 Inhibitors Sales by Region (2019-2024) & (K Units)
 Table 18. Global HER2 Inhibitors Sales Market Share by Region (2019-2024)
 Table 19. Global HER2 Inhibitors Sales by Region (2025-2030) & (K Units)
 Table 20. Global HER2 Inhibitors Sales Market Share by Region (2025-2030)
 Table 21. Global HER2 Inhibitors Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global HER2 Inhibitors Revenue Market Share by Region (2019-2024)
 Table 23. Global HER2 Inhibitors Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global HER2 Inhibitors Revenue Market Share by Region (2025-2030)
 Table 25. North America HER2 Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America HER2 Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 27. North America HER2 Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 28. North America HER2 Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America HER2 Inhibitors Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe HER2 Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe HER2 Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 32. Europe HER2 Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 33. Europe HER2 Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe HER2 Inhibitors Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific HER2 Inhibitors Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific HER2 Inhibitors Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific HER2 Inhibitors Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific HER2 Inhibitors Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific HER2 Inhibitors Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America HER2 Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America HER2 Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America HER2 Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America HER2 Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America HER2 Inhibitors Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa HER2 Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa HER2 Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa HER2 Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa HER2 Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa HER2 Inhibitors Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global HER2 Inhibitors Sales (K Units) by Type (2019-2024)
 Table 51. Global HER2 Inhibitors Sales (K Units) by Type (2025-2030)
 Table 52. Global HER2 Inhibitors Sales Market Share by Type (2019-2024)
 Table 53. Global HER2 Inhibitors Sales Market Share by Type (2025-2030)
 Table 54. Global HER2 Inhibitors Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global HER2 Inhibitors Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global HER2 Inhibitors Revenue Market Share by Type (2019-2024)
 Table 57. Global HER2 Inhibitors Revenue Market Share by Type (2025-2030)
 Table 58. Global HER2 Inhibitors Price (US$/Unit) by Type (2019-2024)
 Table 59. Global HER2 Inhibitors Price (US$/Unit) by Type (2025-2030)
 Table 60. Global HER2 Inhibitors Sales (K Units) by Application (2019-2024)
 Table 61. Global HER2 Inhibitors Sales (K Units) by Application (2025-2030)
 Table 62. Global HER2 Inhibitors Sales Market Share by Application (2019-2024)
 Table 63. Global HER2 Inhibitors Sales Market Share by Application (2025-2030)
 Table 64. Global HER2 Inhibitors Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global HER2 Inhibitors Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global HER2 Inhibitors Revenue Market Share by Application (2019-2024)
 Table 67. Global HER2 Inhibitors Revenue Market Share by Application (2025-2030)
 Table 68. Global HER2 Inhibitors Price (US$/Unit) by Application (2019-2024)
 Table 69. Global HER2 Inhibitors Price (US$/Unit) by Application (2025-2030)
 Table 70. Biocon Company Information
 Table 71. Biocon Description and Business Overview
 Table 72. Biocon HER2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Biocon HER2 Inhibitors Product
 Table 74. Biocon Recent Developments/Updates
 Table 75. Roche Company Information
 Table 76. Roche Description and Business Overview
 Table 77. Roche HER2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Roche HER2 Inhibitors Product
 Table 79. Roche Recent Developments/Updates
 Table 80. AbbVie Company Information
 Table 81. AbbVie Description and Business Overview
 Table 82. AbbVie HER2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. AbbVie HER2 Inhibitors Product
 Table 84. AbbVie Recent Developments/Updates
 Table 85. Merck Sharp & Dohme Company Information
 Table 86. Merck Sharp & Dohme Description and Business Overview
 Table 87. Merck Sharp & Dohme HER2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Merck Sharp & Dohme HER2 Inhibitors Product
 Table 89. Merck Sharp & Dohme Recent Developments/Updates
 Table 90. Novartis Company Information
 Table 91. Novartis Description and Business Overview
 Table 92. Novartis HER2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Novartis HER2 Inhibitors Product
 Table 94. Novartis Recent Developments/Updates
 Table 95. Mylan Company Information
 Table 96. Mylan Description and Business Overview
 Table 97. Mylan HER2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Mylan HER2 Inhibitors Product
 Table 99. Mylan Recent Developments/Updates
 Table 100. Puma Biotechnology Company Information
 Table 101. Puma Biotechnology Description and Business Overview
 Table 102. Puma Biotechnology HER2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Puma Biotechnology HER2 Inhibitors Product
 Table 104. Puma Biotechnology Recent Developments/Updates
 Table 105. Pfizer Company Information
 Table 106. Pfizer Description and Business Overview
 Table 107. Pfizer HER2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Pfizer HER2 Inhibitors Product
 Table 109. Pfizer Recent Developments/Updates
 Table 110. Boehringer Ingelheim Company Information
 Table 111. Boehringer Ingelheim Description and Business Overview
 Table 112. Boehringer Ingelheim HER2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Boehringer Ingelheim HER2 Inhibitors Product
 Table 114. Boehringer Ingelheim Recent Developments/Updates
 Table 115. Johnson & Johnson Company Information
 Table 116. Johnson & Johnson Description and Business Overview
 Table 117. Johnson & Johnson HER2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Johnson & Johnson HER2 Inhibitors Product
 Table 119. Johnson & Johnson Recent Developments/Updates
 Table 120. Genentech Company Information
 Table 121. Genentech Description and Business Overview
 Table 122. Genentech HER2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. Genentech HER2 Inhibitors Product
 Table 124. Genentech Recent Developments/Updates
 Table 125. GlaxoSmithKline Company Information
 Table 126. GlaxoSmithKline Description and Business Overview
 Table 127. GlaxoSmithKline HER2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. GlaxoSmithKline HER2 Inhibitors Product
 Table 129. GlaxoSmithKline Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. HER2 Inhibitors Distributors List
 Table 133. HER2 Inhibitors Customers List
 Table 134. HER2 Inhibitors Market Trends
 Table 135. HER2 Inhibitors Market Drivers
 Table 136. HER2 Inhibitors Market Challenges
 Table 137. HER2 Inhibitors Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of HER2 Inhibitors
 Figure 2. Global HER2 Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global HER2 Inhibitors Market Share by Type: 2023 & 2030
 Figure 4. Monotherapy Product Picture
 Figure 5. Combination Therapy Product Picture
 Figure 6. Global HER2 Inhibitors Market Value by Application (2024-2030) & (US$ Million)
 Figure 7. Global HER2 Inhibitors Market Share by Application: 2023 & 2030
 Figure 8. Stomach Cancer
 Figure 9. Adenocarcinoma
 Figure 10. Cellular Cancer
 Figure 11. Other
 Figure 12. Global HER2 Inhibitors Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 13. Global HER2 Inhibitors Market Size (2019-2030) & (US$ Million)
 Figure 14. Global HER2 Inhibitors Sales (2019-2030) & (K Units)
 Figure 15. Global HER2 Inhibitors Average Price (US$/Unit) & (2019-2030)
 Figure 16. HER2 Inhibitors Report Years Considered
 Figure 17. HER2 Inhibitors Sales Share by Manufacturers in 2023
 Figure 18. Global HER2 Inhibitors Revenue Share by Manufacturers in 2023
 Figure 19. Global 5 and 10 Largest HER2 Inhibitors Players: Market Share by Revenue in HER2 Inhibitors in 2023
 Figure 20. HER2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 21. Global HER2 Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 22. North America HER2 Inhibitors Sales Market Share by Country (2019-2030)
 Figure 23. North America HER2 Inhibitors Revenue Market Share by Country (2019-2030)
 Figure 24. United States HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Canada HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 26. Europe HER2 Inhibitors Sales Market Share by Country (2019-2030)
 Figure 27. Europe HER2 Inhibitors Revenue Market Share by Country (2019-2030)
 Figure 28. Germany HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. France HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. U.K. HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Italy HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Russia HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Asia Pacific HER2 Inhibitors Sales Market Share by Region (2019-2030)
 Figure 34. Asia Pacific HER2 Inhibitors Revenue Market Share by Region (2019-2030)
 Figure 35. China HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. Japan HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. South Korea HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. India HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. Australia HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. China Taiwan HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Southeast Asia HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. Latin America HER2 Inhibitors Sales Market Share by Country (2019-2030)
 Figure 43. Mexico HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Brazil HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Argentina HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Colombia HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Middle East and Africa HER2 Inhibitors Sales Market Share by Country (2019-2030)
 Figure 48. Middle East and Africa HER2 Inhibitors Revenue Market Share by Country (2019-2030)
 Figure 49. Turkey HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. Saudi Arabia HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. UAE HER2 Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. Global Sales Market Share of HER2 Inhibitors by Type (2019-2030)
 Figure 53. Global Revenue Market Share of HER2 Inhibitors by Type (2019-2030)
 Figure 54. Global HER2 Inhibitors Price (US$/Unit) by Type (2019-2030)
 Figure 55. Global Sales Market Share of HER2 Inhibitors by Application (2019-2030)
 Figure 56. Global Revenue Market Share of HER2 Inhibitors by Application (2019-2030)
 Figure 57. Global HER2 Inhibitors Price (US$/Unit) by Application (2019-2030)
 Figure 58. HER2 Inhibitors Value Chain
 Figure 59. HER2 Inhibitors Production Process
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Accenture